Pharma
Pfizer Doubles Down on Obesity with $7.3B Metsera Deal: What It Means for the Weight Loss Arms Race
The obesity drug market is heating up fast, and Pfizer just made a major play. Their acquisition of Metsera for up to $7.3 billion shows
The obesity drug market is heating up fast, and Pfizer just made a major play. Their acquisition of Metsera for up to $7.3 billion shows
Strategic deal creates diversified specialty company with strong acute care presence and immediate revenue diversification CorMedix Inc. announced the completion of its $300 million acquisition
Exclusive U.S. licensing deal aims to reshape colorectal cancer screening landscape Exact Sciences secured exclusive U.S. commercialization rights to Freenome’s blood-based colorectal cancer screening test
Belgian specialty pharma gains pediatric cancer franchise and FDA priority review voucher Belgian specialty pharmaceutical company SERB Pharmaceuticals announced an all-cash $412 million acquisition of
French pharma giant expands neuroscience pipeline with Boston biotech’s microglial disease expertise Sanofi announced its intention to acquire all remaining shares of Vigil Neuroscience for
The Federal Trade Commission has filed a lawsuit to prevent Edwards Lifesciences from completing its $945 million acquisition of JenaValve Technology, marking a significant regulatory